Onconova Therapeutics Inc. (ONTX) Shares Up 4.8%
Onconova Therapeutics Inc. (NASDAQ:ONTX) shot up 4.8% during trading on Tuesday . The company traded as high as $2.83 and last traded at $2.83, with a volume of 80,316 shares trading hands. The stock had previously closed at $2.70.
Separately, Maxim Group reiterated a “buy” rating and set a $6.00 target price on shares of Onconova Therapeutics in a report on Friday, August 19th.
The company’s market cap is $17.94 million. The company’s 50 day moving average price is $3.28 and its 200 day moving average price is $4.52.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/onconova-therapeutics-inc-ontx-shares-up-4-8.html
Onconova Therapeutics (NASDAQ:ONTX) last issued its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($1.96) earnings per share (EPS) for the quarter. The business had revenue of $2.25 million for the quarter. Onconova Therapeutics had a negative return on equity of 256.32% and a negative net margin of 102.42%. On average, equities analysts forecast that Onconova Therapeutics Inc. will post ($2.15) earnings per share for the current year.
An institutional investor recently raised its position in Onconova Therapeutics stock. Renaissance Technologies LLC raised its stake in Onconova Therapeutics Inc. (NASDAQ:ONTX) by 86.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,704 shares of the biopharmaceutical company’s stock after buying an additional 130,404 shares during the period. Renaissance Technologies LLC owned about 1.13% of Onconova Therapeutics worth $163,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.68% of the company’s stock.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.